サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1786996

デュピクセント市場、規模、シェア、動向、産業分析レポート：適応症別、流通チャネル別、地域別-2025年～2034年市場予測

Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region - Market Forecast, 2025-2034

出版日
ページ情報
英文 125 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
デュピクセント市場、規模、シェア、動向、産業分析レポート：適応症別、流通チャネル別、地域別-2025年～2034年市場予測
出版日: 2025年07月01日
発行: Polaris Market Research
ページ情報: 英文 125 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、デュピクセントの世界市場規模は2034年までに287億米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

デュピクセント市場は、2型炎症に関与する特定のタンパク質を標的とする生物学的製剤であるデュピルマブの世界の商業状況を指します。この市場には、デュピルマブの研究開発から製造、流通、販売、そして最終的には患者による使用に至るまで、あらゆる側面が含まれます。デュピクセントは主に、中等度から重度のアトピー性皮膚炎、喘息、鼻ポリープを伴う慢性鼻副鼻腔炎、好酸球性食道炎、結節性痒疹、慢性閉塞性肺疾患の一種など、さまざまな慢性炎症性疾患の治療に用いられる処方箋専用薬です。この市場は、製薬会社、ヘルスケアプロバイダー、そしてこの先進治療の恩恵を受ける患者を含むバリューチェーン全体を包含しています。

デュピクセント市場は、2型炎症に対する理解の深まりと、関連する慢性疾患の治療における大きなアンメットニーズによって、大きな成長と進化を遂げています。デュピクセントは当初、アトピー性皮膚炎を適応症として承認されたが、その後、さまざまな適応症や年齢層で承認されたことが市場拡大に大きく影響し、汎用性の高い治療選択肢となっています。デュピクセントの作用機序は、インターロイキン-4（IL-4）とインターロイキン-13（IL-13）経路のシグナル伝達を阻害することであり、従来の治療法とは一線を画し、これらの複雑な病態を管理するための的を絞ったアプローチを提供します。このため、処方医と患者の双方から高い支持を得ており、世界の医薬品市場におけるデュピクセントの存在感を高めています。

デュピクセント市場レポートハイライト

適応症別では、アトピー性皮膚炎（AD）が2024年に最大のシェアを占める。アトピー性皮膚炎は広く蔓延しており、デュピクセントは中等症から重症のアトピー性皮膚炎に対する有効性を確立していることから、同市場における主導的な地位と継続的な需要が確保されています。

流通チャネル別では、2024年にデュピクセントの流通で最大のシェアを占めたのは病院薬局でした。これは主に、デュピクセントが特殊な生物学的製剤であるため、初期投与や綿密なモニタリングを病院内で行う必要がある場合が多く、医療専門家がその特殊な取り扱いや患者教育の必要性を管理できる体制を整えているためです。

地域別では、北米がデュピクセント市場をリードしています。この優位性は、高度なヘルスケアインフラ、革新的な生物学的製剤に対する高い認知度と受容性、有利な償還政策、2型炎症性疾患を患う患者数の多さなどに起因しています。アジア太平洋は、市場にとってダイナミックで高成長の地域へと急浮上しています。この成長は、ヘルスケアインフラの改善、可処分所得の増加、慢性炎症性疾患に対する高度な治療オプションに対する意識の高まりなど、いくつかの要因によって推進されています。

同市場の主要企業には、サノフィやリジェネロン社などがあります。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 デュピクセントの世界市場の洞察

  • 市場スナップショット
  • デュピクセント市場力学
  • パイプライン分析
  • 市場集中度と特徴
    • 促進要因と機会
      • 2型炎症性疾患の有病率の上昇
      • 承認適応症および年齢層の拡大
    • 抑制要因と課題
      • 高額な治療費
  • PESTEL分析
  • デュピクセント市場動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 世界のデュピクセント市場：適応症別

  • 主な調査結果
  • イントロダクション
  • アトピー性皮膚炎（AD）
  • 喘息
  • 鼻ポリープを伴う慢性副鼻腔炎（CRSwNP）
  • 慢性閉塞性肺疾患（COPD）
  • その他

第6章 世界のデュピクセント市場：流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 病院薬局
  • 小売薬局
  • その他

第7章 世界のデュピクセント市場：地域別

  • 主な調査結果
  • イントロダクション
    • デュピクセント市場評価：地域、2020年～2034年
  • 北米
    • 北米：適応症別、2020年～2034年
    • 北米：流通チャネル別、2020年～2034年
    • 米国
    • カナダ
  • 欧州
    • 欧州：適応症別、2020年～2034年
    • 欧州：流通チャネル別、2020年～2034年
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • オランダ
    • ロシア
    • その他欧州
  • アジア太平洋
    • アジア太平洋：適応症別、2020年～2034年
    • アジア太平洋：流通チャネル別、2020年～2034年
    • 中国
    • インド
    • マレーシア
    • 日本
    • インドネシア
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • 中東・アフリカ：適応症別、2020年～2034年
    • 中東・アフリカ：流通チャネル別、2020年～2034年
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ
  • ラテンアメリカ
    • ラテンアメリカ：兆候別、2020年～2034年
    • ラテンアメリカ：流通チャネル別、2020年～2034年
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他ラテンアメリカ

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第9章 企業プロファイル

  • Regeneron Pharmaceuticals
  • Sanofi
図表

List of Tables:

  • Table 1 Global Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 2 Global Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 3 North America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 4 North America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 5 U.S.: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 6 U.S.: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 7 Canada: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 8 Canada: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 9 Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 10 Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 11 UK: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 12 UK: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 13 France: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 14 France: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 15 Germany: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 16 Germany: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 17 Italy: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 18 Italy: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 19 Spain: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 20 Spain: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 21 Netherlands: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 22 Netherlands: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 23 Russia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 24 Russia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 25 Rest of Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 26 Rest of Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 27 Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 28 Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 29 China: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 30 China: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 31 India: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 32 India: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 33 Malaysia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 34 Malaysia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 35 Japan: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 36 Japan: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 37 Indonesia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 38 Indonesia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 39 South Korea: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 40 South Korea: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 41 Australia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 42 Australia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 43 Rest of Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 44 Rest of Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 45 Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 46 Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 47 Saudi Arabia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 48 Saudi Arabia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 49 UAE: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 50 UAE: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 51 Israel: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 52 Israel: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 53 South Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 54 South Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 55 Rest of Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 56 Rest of Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 57 Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 58 Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 59 Mexico: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 60 Mexico: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 61 Brazil: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 62 Brazil: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 63 Argentina: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 64 Argentina: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • Table 65 Rest of Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • Table 66 Rest of Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Dupixent Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Indication
  • Figure 7. Global Dupixent Market, by Indication, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Distribution Channel
  • Figure 9. Global Dupixent Market, by Distribution Channel, 2024 & 2034 (USD Billion)
目次
Product Code: PM5988

The global dupixent market size is expected to reach USD 28.70 billion by 2034, according to a new study by Polaris Market Research. The report "Dupixent Market Size, Share, Trends, Industry Analysis Report By Indication [Atopic Dermatitis (AD), Asthma, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)], By Distribution Channel, By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The Dupixent market refers to the global commercial landscape for dupilumab, a biologic medication that targets specific proteins involved in type 2 inflammation. This market includes all aspects from the research and development of dupilumab to its manufacturing, distribution, and sale, and ultimately its use by patients. Dupixent is a prescription-only medication primarily used to treat a range of chronic inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and a specific type of chronic obstructive pulmonary disease. The market encompasses the entire value chain, involving pharmaceutical companies, healthcare providers, and the patients who benefit from this advanced therapy.

The Dupixent market has seen considerable growth and evolution, driven by the increasing understanding of type 2 inflammation and the significant unmet needs in treating associated chronic diseases. Initially approved for atopic dermatitis, Dupixent's market expansion has been greatly influenced by its subsequent regulatory approvals across various indications and age groups, making it a versatile treatment option. Its mechanism of action, which involves inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, differentiates it from traditional treatments and offers a targeted approach to managing these complex conditions. This has led to strong adoption among both prescribers and patients, contributing to its substantial presence in the global pharmaceutical landscape.

Dupixent Market Report Highlights

By indication, the atopic dermatitis (AD) segment held the largest share in 2024. Its widespread prevalence and Dupixent's established efficacy in treating moderate-to-severe forms of this chronic skin condition have ensured its leading position and continued demand within the market.

By distribution channel, the hospital pharmacies segment held the largest share in 2024 in Dupixent distribution. This is primarily because Dupixent, as a specialized biologic, often requires initial administration or close monitoring in a hospital setting, where healthcare professionals are equipped to manage its specific handling and patient education needs.

By region, North America is leading in the Dupixent market. This dominance is driven by its advanced healthcare infrastructure, high awareness and acceptance of innovative biologic therapies, favorable reimbursement policies, and a significant patient population suffering from type 2 inflammatory diseases. Asia Pacific is rapidly emerging as a dynamic and high-growth region for the market. This growth is propelled by several factors, including improving healthcare infrastructure, rising disposable incomes, and increasing awareness of advanced treatment options for chronic inflammatory diseases.

Key players in the market include Sanofi and Regeneron Pharmaceuticals.

Polaris Market Research has segmented the Dupixent market report based on indication, distribution channel, and region:

By Indication Outlook (Revenue - USD Billion, 2020-2034)

Atopic Dermatitis (AD)

Asthma

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Chronic Obstructive Pulmonary Disease (COPD)

Others

By Distribution Channel Outlook (Revenue - USD Billion, 2020-2034)

Hospital Pharmacies

Retail Pharmacies

Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

North America

U.S.

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Dupixent Market Insights

  • 4.1. Dupixent Market - Market Snapshot
  • 4.2. Dupixent Market Dynamics
  • 4.3. Pipeline Analysis
  • 4.4. Market Concentration & Characteristics
    • 4.4.1. Drivers and Opportunities
      • 4.4.1.1. Rising Prevalence of Type 2 Inflammatory Diseases
      • 4.4.1.2. Broadening of Approved Indications and Age Groups
    • 4.4.2. Restraints and Challenges
      • 4.4.2.1. High treatment costs
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers (Moderate)
    • 4.5.2. Threats of New Entrants: (Low)
    • 4.5.3. Bargaining Power of Buyers (Moderate)
    • 4.5.4. Threat of Substitute (Moderate)
    • 4.5.5. Rivalry among existing firms (High)
  • 4.6. PESTEL Analysis
  • 4.7. Dupixent Market Trends
  • 4.8. Value Chain Analysis
  • 4.9. COVID-19 Impact Analysis

5. Global Dupixent Market, by Indication

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Dupixent Market, by Indication, 2020-2034 (USD Billion)
  • 5.3. Atopic Dermatitis (AD)
    • 5.3.1. Global Dupixent Market, by Atopic Dermatitis (AD), by Region, 2020-2034 (USD Billion)
  • 5.4. Asthma
    • 5.4.1. Global Dupixent Market, by Asthma, by Region, 2020-2034 (USD Billion)
  • 5.5. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 5.5.1. Global Dupixent Market, by Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), by Region, 2020-2034 (USD Billion)
  • 5.6. Chronic Obstructive Pulmonary Disease (COPD)
    • 5.6.1. Global Dupixent Market, by Chronic Obstructive Pulmonary Disease (COPD), by Region, 2020-2034 (USD Billion)
  • 5.7. Others
    • 5.7.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Dupixent Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Dupixent Market, by Hospital Pharmacies, by Region, 2020-2034 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Dupixent Market, by Retail Pharmacies, by Region, 2020-2034 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Dupixent Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Dupixent Market, by Geography

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Dupixent Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 7.3. Dupixent Market - North America
    • 7.3.1. North America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
    • 7.3.2. North America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.3.3. Dupixent Market - U.S.
      • 7.3.3.1. U.S.: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.3.3.2. U.S.: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.3.4. Dupixent Market - Canada
      • 7.3.4.1. Canada: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.3.4.2. Canada: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.4. Dupixent Market - Europe
    • 7.4.1. Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
    • 7.4.2. Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.3. Dupixent Market - UK
      • 7.4.3.1. UK: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.3.2. UK: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.4. Dupixent Market - France
      • 7.4.4.1. France: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.4.2. France: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.5. Dupixent Market - Germany
      • 7.4.5.1. Germany: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.5.2. Germany: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.6. Dupixent Market - Italy
      • 7.4.6.1. Italy: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.6.2. Italy: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.7. Dupixent Market - Spain
      • 7.4.7.1. Spain: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.7.2. Spain: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.8. Dupixent Market - Netherlands
      • 7.4.8.1. Netherlands: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.8.2. Netherlands: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.9. Dupixent Market - Russia
      • 7.4.9.1. Russia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.9.2. Russia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.4.10. Dupixent Market - Rest of Europe
      • 7.4.10.1. Rest of Europe: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.4.10.2. Rest of Europe: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.5. Dupixent Market - Asia Pacific
    • 7.5.1. Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
    • 7.5.2. Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.3. Dupixent Market - China
      • 7.5.3.1. China: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.3.2. China: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.4. Dupixent Market - India
      • 7.5.4.1. India: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.4.2. India: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.5. Dupixent Market - Malaysia
      • 7.5.5.1. Malaysia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.5.2. Malaysia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.6. Dupixent Market - Japan
      • 7.5.6.1. Japan: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.6.2. Japan: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.7. Dupixent Market - Indonesia
      • 7.5.7.1. Indonesia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.7.2. Indonesia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.8. Dupixent Market - South Korea
      • 7.5.8.1. South Korea: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.8.2. South Korea: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.9. Dupixent Market - Australia
      • 7.5.9.1. Australia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.9.2. Australia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.5.10. Dupixent Market - Rest of Asia Pacific
      • 7.5.10.1. Rest of Asia Pacific: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.5.10.2. Rest of Asia Pacific: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.6. Dupixent Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
    • 7.6.2. Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.6.3. Dupixent Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.6.4. Dupixent Market - UAE
      • 7.6.4.1. UAE: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.6.4.2. UAE: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.6.5. Dupixent Market - Israel
      • 7.6.5.1. Israel: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.6.5.2. Israel: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.6.6. Dupixent Market - South Africa
      • 7.6.6.1. South Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.6.6.2. South Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.6.7. Dupixent Market - Rest of Middle East & Africa
      • 7.6.7.1. Rest of Middle East & Africa: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.6.7.2. Rest of Middle East & Africa: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
  • 7.7. Dupixent Market - Latin America
    • 7.7.1. Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
    • 7.7.2. Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.7.3. Dupixent Market - Mexico
      • 7.7.3.1. Mexico: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.7.3.2. Mexico: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.7.4. Dupixent Market - Brazil
      • 7.7.4.1. Brazil: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.7.4.2. Brazil: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.7.5. Dupixent Market - Argentina
      • 7.7.5.1. Argentina: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.7.5.2. Argentina: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)
    • 7.7.6. Dupixent Market - Rest of Latin America
      • 7.7.6.1. Rest of Latin America: Dupixent Market, by Indication, 2020-2034 (USD Billion)
      • 7.7.6.2. Rest of Latin America: Dupixent Market, by Distribution Channel, 2020-2034 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Regeneron Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Sanofi
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development